Cover Image
市場調查報告書

美國的糖尿病市場

US Diabetes Market Outlook 2020

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 146121
出版日期 內容資訊 英文 85 Pages
訂單完成後即時交付
價格
Back to Top
美國的糖尿病市場 US Diabetes Market Outlook 2020
出版日期: 2015年08月01日 內容資訊: 英文 85 Pages
簡介

糖尿病在美國市場擴大,估計至2030年糖尿病的盛行率成為14%。並且很多糖尿病患者沒察覺狀況。還有糖尿病相關的醫療費為主題,提供2014年達到約2,810億美元,美對國政府來說成為醫療費龐大負擔。

本報告提供美國的糖尿病市場相關調查分析、各次級市場的市場趨勢、患者簡介、成本等資訊、政府的積極推動、主要企業簡介為您概述為以下內容。

第1章 分析師的見解

第2章 調查手法

第3章 市場概要

第4章 患者簡介分析

第5章 成本的意義

第6章 市場成長的促進要素及課題

  • 市場成長的促進要素
    • 導糖尿病的肥胖
    • 可支配所得的增加
    • 壽命的延長
    • 糖尿病治療相關意識的高漲
  • 課題
    • 糖尿病治療的傳統療法
    • 抗糖尿病藥物和糖尿病治療設備的高額費用
    • 治療藥批審期間長

第7章 糖尿病治療藥市場

  • 口服抗糖尿病藥物市場
  • 胰島素市場

第8章 胰島素給藥設備市場

  • 胰島素幫浦
  • 胰島素筆針
  • 胰島素注射器
  • 胰島素噴射注射器
  • 口服胰島素
  • 吸入胰島素

第9章 血糖儀市場

  • 葡萄糖檢驗紙
  • 採血針
  • 血糖儀
  • 連續血糖值螢幕

第10章 趨勢及發展

  • 糖尿病的簡易檢驗用血糖儀
  • 透過創新藥物管理糖尿病
  • 胰島細胞移植-對糖尿病患者來說是希望之光

第11章 政府的積極推動

第12章 主要企業

  • 製藥
    • Pfizer
    • GlaxoSmithKline
    • 武田藥品工業
    • Merck
  • 胰島素給藥設備
    • Novo Nordisk
    • Eli Lilly
    • Sanofi
    • Medtronic
  • 血糖儀
    • Roche
    • Bayer
    • Abbott Laboratories

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Diabetes has been on the rise for the last few years because of factors such as increased life span of people, hectic lifestyles and increased intake of fatty food. The largest number of cases of diabetes and pre-diabetes are found in the United States, with many still unaware about their diabetes or pre-diabetes condition. It has been estimated that the prevalence of diabetes will be 14% by 2030 in the US. This is likely to put a major burden on healthcare cost of the country. Studies have shown that the total healthcare expenditure in US was US$ 281 Billion in 2014 which was the largest share of the world healthcare expenditure.

The US diabetes care market is segmented into three parts, namely- anti-diabetic drugs segment, insulin delivery devices segment and monitoring and diagnostic devices segment. The most significant growth in the US market has been seen in continuous blood glucose meters, insulin pens, insulin pumps, and anti-diabetic drugs.

The report, “US Diabetes Market Outlook 2020”, highlights the US diabetes market by each segment. The market for each segment has been thoroughly studied and the future market scenario has been forecasted. The prevalence of diabetes and its cost implications have also been indicated in the report. The drivers and challenges of this market have been discussed along with the latest trends and developments. Additionally, information is provided about the key players in this market as well as the steps taken by the government to promote the market. The aforementioned information will help clients in formulating strategies and assessing opportunities in the US diabetes market.

Table of Contents

1. Analyst View

2. Research Methodology

3. Market Overview

4. Patient Profile Analysis

5. Cost Implications

6. Drivers and Challenges

  • 6.1. Drivers for Diabetes Market
    • 6.1.1. Obesity Leading to Diabetes
    • 6.1.2. Rising Disposable Income
    • 6.1.3. Increasing Life Span of People
    • 6.1.4. Increased Awareness about Diabetes Care
  • 6.2. Challenges
    • 6.2.1. Traditional Remedies for Diabetes Care
    • 6.2.2. High Cost of Anti-diabetic Medication and Diagnostic Devices
    • 6.2.3. Long Product Approval Process

7. Diabetes Drugs Market

  • 7.1. Oral Anti-Diabetic Drugs Market
  • 7.2. Insulin Market

8. Insulin Delivery Devices Market

  • 8.1. Insulin Pump
  • 8.2. Insulin Pen
  • 8.3. Insulin Syringes
  • 8.4. Insulin Jet Injectors
  • 8.5. Oral Insulin
  • 8.6. Inhalable Insulin

9. Glucose Monitoring Devices Market

  • 9.1. Glucose Test Strips
  • 9.2. Lancets
  • 9.3. Blood Glucose Meter
  • 9.4. Continuous Blood Glucose Monitors

10. Trends and Developments

  • 10.1. Glucose Meters for Easy Detection of Diabetes
  • 10.2. Novel Drugs Keep Diabetes in Control
  • 10.3. Islet Cell Transplantation- Hope for Diabetes Patients

11. Government Initiatives

12. Competitive Landscape

  • 12.1. Drugs
    • 12.1.1. Pfizer
    • 12.1.2. GlaxoSmithKline
    • 12.1.3. Takeda
    • 12.1.4. Merck
  • 12.2. Insulin Delivery Devices
    • 12.2.1. Novo Nordisk
    • 12.2.2. Eli Lilly
    • 12.2.3. Sanofi
    • 12.2.4. Medtronic Inc.
  • 12.3. Glucose Monitoring Devices
    • 12.3.1. Roche
    • 12.3.2. Bayer
    • 12.3.3. Abbott Laboratories

List of Figures:

  • Figure 3-1: Diabetes Market (Billion US$), 2013 & 2014
  • Figure 4-1: Prevalence of Diabetes (%), 2014 & 2030
  • Figure 4-2: Number of Diabetic Population (Million), 2014 & 2030
  • Figure 5-1: Total Healthcare Expenditure on Diabetes (Billion US$)-US vs. RoW, 2014
  • Figure 5-2: Cost per Person (US$) - US vs. RoW for People with Diabetes, 2014
  • Figure 6-1: Personal Disposable Income (Billion US$), 2008-2014
  • Figure 6-2: Population above 65 Years (Million), 2008-2014
  • Figure 7-1: Oral Diabetic Drugs Market (Billion US$), 2014-2020
  • Figure 7-2: Insulin Market (Billion US$), 2014-2020
  • Figure 7-3: Share of Key Players in Modern Insulin Market (FY 2013)
  • Figure 8-1: Insulin Pumps Market (Billion US$), 2014-2020
  • Figure 8-2: Shares of Key Players in US Insulin Pump Market (2013)
  • Figure 8-3: Insulin Pen Devices Market (Billion US$), 2014-2020
  • Figure 8-4: Insulin Syringes Market (Billion US$), 2014-2020
  • Figure 8-5: Insulin Jet Injectors Market (Billion US$), 2014-2020
  • Figure 9-1: Glucose Test Strips Market (Billion US$), 2014-2020
  • Figure 9-2: Lancets Market (Billion US$), 2014-2020
  • Figure 9-3: Blood Glucose Meter Market (Billion US$), 2014-2020
  • Figure 9-4: Continuous Blood Glucose Monitoring Market (Billion US$), 2014-2020
  • Figure 12-1: Pfizer - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-2: GlaxoSmithKline - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-3: Takeda - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-4: Merck - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-5: Novo Nordisk - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-6: Eli Lilly - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-7: Sanofi - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-8: Medtronic Inc. - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-9: Roche - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-10: Bayer - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-11: Abbott Laboratories - Breakup of Revenue by Geographies (%), 2014

List of Tables:

  • Table 4-1: Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2030
  • Table 12-1: Pfizer - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-2: GlaxoSmithKline - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-3: Takeda - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-4: Merck - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-5: Novo Nordisk - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-6: Eli Lilly - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-7: Sanofi - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-8: Medtronic Inc. - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-9: Roche - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-10: Bayer - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-11: Abbott Laboratories - Revenue by Business Segments (Billion US$), 2013 & 2014
Back to Top